Biotie Therapies - Annual Financial Report

Biotie's Financial Statement Report and Corporate Governance Statement 2014 published

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE                  9 March 2015
at 4:30 p.m.

Biotie's Financial Statement Report and Corporate Governance Statement 2014
published

Biotie Therapies Corp.' s  Financial Statement Report for the financial period
ended 31 December 2014 and  Corporate Governance Statement 2014 have been
published.

The documents are attached in pdf format in this release. Both documents are
also available on Biotie's website www.biotie.com in English and Finnish
language.

Turku, 9 March 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

About Biotie

Biotie is a specialized drug development company focused on products for
neurodegenerative and psychiatric disorders. Biotie's development has delivered
Selincro (nalmefene) for alcohol dependence, which received European marketing
authorization in 2013 and is currently being rolled out across Europe by partner
Lundbeck. The current development products include tozadenant for Parkinson's
disease, which is transitioning into Phase 3 development, and two additional
compounds which are in Phase 2 development for cognitive disorders including
Parkinson's disease dementia, and primary sclerosing cholangitis (PSC), a rare
fibrotic disease of the liver.



Biotie_Financial_Statements_2014
Biotie_Corporate Governance Statement 2014


[HUG#1900357]

Attachments:

Corporate Governance Statement 2014.pdf

Biotie_Financial_Statements_2014.pdf